Morepen Laboratories Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kylbuseavxl4zm3ulh7dsi7v.pdf

Key Takeaways


API Business: Volume Growth, Margin Pressure

Sushil Suri: "when we say API, we are not talking of traditional APIs, we are not talking of paracetamol, and ceflexane, and amoxicillin in the world. We are talking new molecules, with high-gross molecules"

Medical Devices: The Standout Performer


Formulation & OTC: Restructuring for a Turnaround

Sushil Suri: "It's a strategic call. It's easy to burn money and throw money, but naturally we don't have our so called investor's money to burn like our other startups are doing. We are a bit conservative"

Margins & Cost Structure


People, Culture & Systems


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin targetReach double-digit EBITDA marginsNext financial year (FY25)
Revenue growthMaintain 15-20% CAGR (20% outside, 15% bare minimum)Ongoing
Formulation revenue improvementFormulation sales to start increasing, improving bottom linesFrom next quarter (Q4 FY24) onward
Loratadine tender recoveryCustomer may win a government supply tenderLate this year or next year
Dr. Morepen IPO readinessBusiness must reach ₹200-300 crores before IPO (currently ~₹100 crores)Two to three years
API capex funding₹125 crores API capex, preferring debt over equityNot specified
Medical devices capex₹50-75 crores funded from internal cash flowsNot specified

Key Metrics

MetricQ2 FY24
Revenue₹425 cr, +5% YoY
H1 FY24 revenue₹828 cr, +17% YoY
EBITDA+24% YoY
H1 FY24 EBITDA+44% YoY
Profit before tax+29% YoY
Profit after tax₹21.26 cr, +34% YoY
H1 FY24 PAT₹36 cr, +67% YoY
EBITDA margin~8%, up from ~6.5% last year
API segment revenue₹212 cr, +5% QoQ; volume up 25% but realization down 28%
API segment H1 revenue₹415 cr, +5% YoY
Medical devices revenue growth+41% YoY in Q2, +44% in H1
Medical devices H1 revenue₹248 cr, on track to cross ₹400 cr for full year
Glucometer H1 revenue₹195 cr, +42% YoY
Glucometer active customer base1.06 cr
BP monitors H1 growth+52% YoY
Formulation business growth+16% YoY in Q2, +12% in H1
Dr. Morepen OTC H1 revenue₹48 cr, flat YoY
Domestic revenue growth+26% YoY in Q2, +31% in H1
API division EBITDA margin14% to 15% (before corporate expenses)
Medical devices EBITDA margin12% to 13% (before corporate expenses)
Capex plan, API₹125 cr
Capex plan, medical devices₹50 to ₹75 cr
Employee count3,000+
R&D team size36 scientists
US DMFs filed26
Patents held543
New products launched, last 3 years41